NeoGenomics raises 2026 guidance to $807M-$809M while planning CEO transition in January 2027 (NASDAQ:NEO)
· seekingalpha.com
NeoGenomics Q3 2026: revenue rose 11%, NGS surged, and guidance increased.
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
If you have an ad-blocker enabled you may be blocked from ...